Key Sections

Maximizing French R&D Tax Credits: A Guide for U.S. Parent Companies

France runs one of the most generous R&D incentive programs in the world. For a U.S. company with a French engineering team, this represents a massive opportunity. Specifically, the CIR tax credit (Crédit d’Impôt Recherche) can return 30% of eligible R&D expenses against your French tax liability. For a team of ten engineers, this is a significant financial boost.

However, qualifying on paper is not the main challenge. Instead, the problem lies in how U.S. parent companies fund their subsidiaries. Common structures like “cost-plus” arrangements often quietly disqualify the French entity. If you are funding a French team without a structural review, you might be leaving money on the table.

1. CIR vs. CII: Which One Applies to Your Business?

French R&D incentives fall into two main programs. Understanding the difference is vital for your subsidiary’s strategy.

  • CIR: Crédit d’Impôt Recherche This is the flagship CIR tax credit. It covers 30% of eligible expenses, including salaries and operating costs, up to €100 million. It applies to fundamental and applied research aimed at resolving genuine technical uncertainties.
  • CII: Crédit d’Impôt Innovation Designed for SMEs, the CII covers 30% of costs related to designing prototypes or new products. While it is narrower in scope than the CIR, it remains highly valuable for smaller subsidiaries at the product development stage.

One strict rule applies to both: only work physically performed in France is eligible. You cannot attribute research done by your U.S. team or offshore contractors to the French program.

2. The Funding Trap: Why Money Flows Matter

This is where most U.S. operators unknowingly lose their eligibility. The payment structure from the U.S. parent to the French subsidiary is the central question during a CIR tax credit audit.

In a standard “cost-plus” arrangement, the parent pays the subsidiary a fee for services. Consequently, French tax authorities may conclude that the parent is “buying” the research. Under this interpretation, the subsidiary must deduct those payments from its eligible expenses. In practice, this often zeros out the credit entirely.

To avoid this, you should consider structuring the funding as an operating subsidy or a capital contribution. This allows the French entity to “own” the research expenses. While the distinction sounds subtle, the financial difference is immense.

3. Transfer Pricing and Economic Substance

Even with the correct funding, authorities run a dual audit on CIR tax credit claims. They examine both the scientific file and the transfer pricing. Specifically, they want to see “economic substance.”

To defend a claim, the French subsidiary must demonstrate that it carries the technical and financial risk. It must have genuine decision-making authority over the project. If your intercompany agreement automatically transfers all IP to the U.S. parent, authorities may argue that the subsidiary is merely a service provider. In that case, the CIR tax credit does not apply.

4. What to Do Before Tax Season

If you are planning to file a claim, ensure these three things are in order:

  1. Review Intercompany Agreements: Make sure the French entity is not positioned as a no-risk service provider. It must retain meaningful control over the research and IP during the eligible period.
  2. Build Documentation Early: The CIR tax credit requires a technical “Scientific File” and a “Financial File.” These documents are far harder to reconstruct after an audit has begun.
  3. Check the U.S. Side: The French CIR and the U.S. R&D credit (Section 41) are not mutually exclusive. Both programs can run alongside each other if they cover distinct activities.

Conclusion: Turning Research into a Material Return

The CIR tax credit is one of the most valuable incentives for technical work in France. Often, U.S. companies fail to benefit because their funding structure disqualifies them before work even begins. By fixing your intercompany agreements and documenting your substance, the credit becomes a reliable return on your French R&D investment.